JP6140151B2 - 統合失調症の処置において４−（（１ｒ，３ｓ）−６−クロロ−３−フェニル−インダン−１−イル）−１，２，２−トリメチル−ピペラジンおよびその塩を投与する方法 - Google Patents
統合失調症の処置において４−（（１ｒ，３ｓ）−６−クロロ−３−フェニル−インダン−１−イル）−１，２，２−トリメチル−ピペラジンおよびその塩を投与する方法 Download PDFInfo
- Publication number
- JP6140151B2 JP6140151B2 JP2014516318A JP2014516318A JP6140151B2 JP 6140151 B2 JP6140151 B2 JP 6140151B2 JP 2014516318 A JP2014516318 A JP 2014516318A JP 2014516318 A JP2014516318 A JP 2014516318A JP 6140151 B2 JP6140151 B2 JP 6140151B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- week
- schizophrenia
- dose
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161498653P | 2011-06-20 | 2011-06-20 | |
| DKPA201100465 | 2011-06-20 | ||
| US61/498,653 | 2011-06-20 | ||
| DKPA201100465 | 2011-06-20 | ||
| PCT/EP2012/061779 WO2012175531A1 (en) | 2011-06-20 | 2012-06-20 | Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014517050A JP2014517050A (ja) | 2014-07-17 |
| JP2014517050A5 JP2014517050A5 (enExample) | 2016-11-17 |
| JP6140151B2 true JP6140151B2 (ja) | 2017-05-31 |
Family
ID=58794324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014516318A Active JP6140151B2 (ja) | 2011-06-20 | 2012-06-20 | 統合失調症の処置において４−（（１ｒ，３ｓ）−６−クロロ−３−フェニル−インダン−１−イル）−１，２，２−トリメチル−ピペラジンおよびその塩を投与する方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9610287B2 (enExample) |
| EP (1) | EP2720698B1 (enExample) |
| JP (1) | JP6140151B2 (enExample) |
| KR (1) | KR101900989B1 (enExample) |
| CN (1) | CN103608015A (enExample) |
| AU (1) | AU2012274150B2 (enExample) |
| BR (1) | BR112013032178A2 (enExample) |
| CA (1) | CA2838055C (enExample) |
| DK (1) | DK2720698T3 (enExample) |
| ES (1) | ES2694298T3 (enExample) |
| HR (1) | HRP20181684T1 (enExample) |
| IL (1) | IL230060A (enExample) |
| JO (1) | JO3421B1 (enExample) |
| LT (1) | LT2720698T (enExample) |
| MX (1) | MX349754B (enExample) |
| PL (1) | PL2720698T3 (enExample) |
| RS (1) | RS57944B1 (enExample) |
| RU (1) | RU2613177C2 (enExample) |
| SI (1) | SI2720698T1 (enExample) |
| SM (1) | SMT201800567T1 (enExample) |
| TW (1) | TWI552751B (enExample) |
| WO (1) | WO2012175531A1 (enExample) |
| ZA (1) | ZA201309617B (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7402400B2 (en) | 2001-07-03 | 2008-07-22 | Regents Of The University Of California | Mammalian sweet taste receptors |
| CA2390600A1 (en) | 1999-11-17 | 2001-05-25 | Mendel Biotechnology, Inc. | Seed trait genes |
| US6458538B1 (en) | 1999-12-14 | 2002-10-01 | Ptc Therapeutics, Inc. | Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay |
| TW201006846A (en) | 2000-03-07 | 2010-02-16 | Senomyx Inc | T1R taste receptor and genes encidung same |
| EP1406483A4 (en) | 2000-08-22 | 2005-05-25 | Mendel Biotechnology Inc | GENE FOR CHANGING THE PROPERTIES OF PLANTS |
| US7045283B2 (en) | 2000-10-18 | 2006-05-16 | The Regents Of The University Of California | Methods of high-throughput screening for internalizing antibodies |
| US7883856B2 (en) | 2001-04-05 | 2011-02-08 | Senomyx Inc. | Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators |
| AU2002326315B2 (en) | 2001-06-26 | 2007-07-05 | Senomyx, Inc. | T1R hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds |
| US7871619B2 (en) | 2001-11-30 | 2011-01-18 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| CA2492883C (en) | 2002-08-01 | 2012-10-02 | James D. Marks | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| AU2003243151A1 (en) | 2002-08-16 | 2004-03-03 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
| ES2380017T3 (es) | 2002-09-18 | 2012-05-07 | Mendel Biotechnology, Inc. | Polinucleótidos y polipéptidos en plantas |
| CN101090729B (zh) | 2003-05-30 | 2014-07-23 | 艾更斯司股份有限公司 | 前列腺干细胞抗原(psca)变体及其序列 |
| JP4796967B2 (ja) | 2003-11-07 | 2011-10-19 | ヴァーミリオン インコーポレイテッド | アルツハイマー病のためのバイオマーカー |
| WO2005060739A1 (en) | 2003-12-24 | 2005-07-07 | G2 Inflammation Pty Ltd | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar |
| DK1734996T3 (da) | 2004-04-02 | 2013-06-10 | Univ California | Fremgangsmåder og sammensætninger til behandling og forebyggelse af sygdom, der er associeret med alfa v beta 5-integrin |
| US7939251B2 (en) | 2004-05-06 | 2011-05-10 | Roche Molecular Systems, Inc. | SENP1 as a marker for cancer |
| WO2005118864A2 (en) | 2004-05-28 | 2005-12-15 | Agensys, Inc. | Antibodies and related molecules that bind to psca proteins |
| WO2006002262A2 (en) | 2004-06-21 | 2006-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder |
| US7850960B2 (en) | 2004-12-30 | 2010-12-14 | University Of Washington | Methods for regulation of stem cells |
| US7700738B2 (en) | 2005-01-27 | 2010-04-20 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| RU2413735C2 (ru) | 2005-03-31 | 2011-03-10 | Эдженсис, Инк. | Антитела и родственные молекулы, связывающиеся с белками 161p2f10b |
| HRP20181379T1 (hr) | 2005-07-19 | 2018-11-16 | Stemgen S.P.A. | Inhibiranje tumorogenog potencijala tumorskih matičnih stanica s bmp-4 |
| WO2007047988A2 (en) | 2005-10-20 | 2007-04-26 | Senomyx, Inc. | Chimeric human sweet-umami and umami-sweet taste receptors |
| UA94922C2 (ru) | 2005-11-07 | 2011-06-25 | Зе Скріпс Рісьорч Інстітьют | Способ регулирования специфичности сигнализации тканевого фактора у млекопитающего, которое нуждается в этом, способ идентификации агента, который специфически ингибирует сигнализацию тканевого фактора |
| AU2006315562C1 (en) | 2005-11-12 | 2013-10-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating depression using NCAM peptide mimetics |
| JP5713377B2 (ja) | 2005-12-28 | 2015-05-07 | ザ スクリプス リサーチ インスティテュート | 薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物 |
| US20100278821A1 (en) | 2006-03-21 | 2010-11-04 | The Regents Of The University Of California | N-cadherin: target for cancer diagnosis and therapy |
| AU2007227195A1 (en) | 2006-03-21 | 2007-09-27 | The Regents Of The University Of California | N-cadherin and Ly6 E: targets for cancer diagnosis and therapy |
| US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
| US20100292090A1 (en) | 2006-08-25 | 2010-11-18 | Oncotherapy Science, Inc. | Prognostic markers and therapeutic targets for lung cancer |
| EP2679999A1 (en) | 2006-09-06 | 2014-01-01 | The Regents of the University of California | Molecular diagnosis and classification of malignant melanoma |
| EP2095100B1 (en) | 2006-11-22 | 2016-09-21 | President and Fellows of Harvard College | Method of operating a nanowire field effect transistor sensor |
| IN2009KN04568A (enExample) | 2007-06-01 | 2015-08-28 | Univ Princeton | |
| US7968293B2 (en) | 2007-08-13 | 2011-06-28 | Baxter International Inc. | IVIG modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease |
| RU2522456C2 (ru) | 2007-08-21 | 2014-07-10 | Синомикс, Инк. | Соединения, ингибирующие (блокирующие) горький вкус, способы их применения и получения |
| EA201000343A1 (ru) | 2007-10-04 | 2011-10-31 | Займодженетикс, Инк. | ЧЛЕН СЕМЕЙСТВА B7, zB7H6 И РОДСТВЕННЫЕ КОМПОЗИЦИИ И СПОСОБЫ |
| EP2924435A3 (en) | 2007-10-22 | 2015-11-04 | The Regents of The University of California | Biomarkers for prenatal diagnosis of congenital cytomegalovirus |
| EP2219671A4 (en) | 2007-11-09 | 2011-02-09 | Salk Inst For Biological Studi | USE OF TAM RECEPTOR INHIBITORS AS IMMU ENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS |
| SG10202103401QA (en) | 2008-03-17 | 2021-05-28 | Scripps Research Inst | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
| CA2721980C (en) | 2008-04-21 | 2017-01-03 | The Regents Of The University Of California | Selective high-affinity poly dentate ligands and methods of making such |
| WO2010017248A2 (en) | 2008-08-04 | 2010-02-11 | University Of Miami | Sting (stimulator of interferon genes), a regulator of innate immune responses |
| CN102224254A (zh) | 2008-09-23 | 2011-10-19 | 哈佛大学校长及研究员协会 | Sirt4及其用途 |
| EP3260123A1 (en) | 2008-11-06 | 2017-12-27 | University of Miami | Role of soluble upar in the pathogenesis of proteinuric kidney disease |
| EP2352847B1 (en) | 2008-11-10 | 2014-01-08 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Gene signature for predicting prognosis of patients with solid tumors |
| AU2009322346B2 (en) | 2008-12-03 | 2015-07-02 | The Scripps Research Institute | Stem cell cultures |
| CN102317442B (zh) | 2008-12-17 | 2014-08-13 | 斯克里普斯研究所 | 干细胞的产生和保持 |
| US20100291100A1 (en) | 2009-03-27 | 2010-11-18 | Gojo Industries, Inc. | Compositions And Methods For Screening And Using Compounds Antagonizing Spore-Surface Interactions |
| AU2010275367B2 (en) | 2009-07-24 | 2015-09-03 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with avB5 integrin |
| CA2771102C (en) | 2009-08-14 | 2019-10-15 | The Regents Of The University Of California | Methods of diagnosing and treating autism |
| US20120148604A1 (en) | 2009-08-20 | 2012-06-14 | Transposagen Biopharmaceuticals, Inc. | Trp inhibitors and uses thereof |
| WO2011038228A1 (en) | 2009-09-24 | 2011-03-31 | President And Fellows Of Harvard College | Bent nanowires and related probing of species |
| ES2365343B1 (es) | 2009-11-19 | 2012-07-10 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Uso de cd98 como marcador de receptividad endometrial. |
| WO2011094759A2 (en) | 2010-02-01 | 2011-08-04 | The Regents Of The University Of California | Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies |
| WO2012052391A1 (en) | 2010-10-19 | 2012-04-26 | Glaxo Group Limited | Polypeptide with jmjd3 catalytic activity |
| WO2012109495A1 (en) | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
| WO2012119989A2 (en) | 2011-03-04 | 2012-09-13 | Oryzon Genomics, S.A. | Methods and antibodies for the diagnosis and treatment of cancer |
| US20120301904A1 (en) | 2011-04-26 | 2012-11-29 | Prosetta Antiviral, Inc | Multiprotein assemblies |
| EP2825210B1 (en) | 2012-03-14 | 2019-06-26 | University of Central Florida Research Foundation, Inc. | Lim kinasemodulating agents for neurofibromatoses therapy and methods for screening for same |
| EP2836482B1 (en) | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
| CA2871462A1 (en) | 2012-04-24 | 2013-10-31 | University Of Miami | Perforin 2 defense against invasive and multidrug resistant pathogens |
| EP3184121A3 (en) | 2012-07-25 | 2017-09-27 | Salk Institute For Biological Studies | Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases |
| EP2890370B1 (en) | 2012-08-31 | 2019-10-09 | The Regents of the University of California | Agents useful for treating obesity, diabetes and related disorders |
| AU2013204200B2 (en) | 2012-10-11 | 2016-10-20 | Brandeis University | Treatment of amyotrophic lateral sclerosis |
| US20140120116A1 (en) | 2012-10-26 | 2014-05-01 | The Chinese University Of Hong Kong | Treatment of cancer using smad3 inhibitor |
| DK2954323T3 (da) | 2013-02-07 | 2020-07-20 | Univ California | Anvendelse af translationsprofilering til identifikation af målmolekyler til terapeutisk behandling |
| US9428537B2 (en) | 2013-03-15 | 2016-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | tRNA derived small RNAs (tsRNAs) involved in cell viability |
| EP3080122B1 (en) | 2013-12-11 | 2018-10-31 | Biogen MA Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| WO2015089338A2 (en) | 2013-12-11 | 2015-06-18 | Sloan-Kettering Institute For Cancer Research | Glucocorticoid inhibitors for treatment of prostate cancer |
| WO2015136509A2 (en) | 2014-03-14 | 2015-09-17 | Genesis Theranostix Korlatolt Felelossegu Tarsasag | Diagnostic and therapeutic targets for preeclampsia and closely related complications of pregnancy |
| US10196701B2 (en) | 2015-06-01 | 2019-02-05 | The Penn State Research Foundation | Hepatitis B virus capsid assembly |
| EP3314260B1 (en) | 2015-06-24 | 2021-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for detecting protein-protein interactions |
| WO2018036503A1 (en) | 2016-08-25 | 2018-03-01 | The Chinese University Of Hong Kong | Fecal bacterial markers for colorectal cancer |
| KR20190095355A (ko) | 2016-12-15 | 2019-08-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암의 치료를 위한 조성물 및 방법 |
| US11555031B2 (en) | 2017-03-20 | 2023-01-17 | The Broad Institute, Inc. | Compounds and methods for regulating insulin secretion |
| US12016902B2 (en) | 2017-04-04 | 2024-06-25 | Loma Linda University | Biologic for the treatment of cancer |
| US20210247386A1 (en) | 2018-04-26 | 2021-08-12 | Technion Research & Development Foundation Limited | A device and method for determining cell indentation activity |
| AU2019373090B2 (en) | 2018-10-31 | 2023-05-25 | The University Of Sydney | Compositions and methods for treating viral infections |
| WO2020097261A1 (en) | 2018-11-06 | 2020-05-14 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | New compositions and methods for treating beta-globinopathies |
| US20240301510A1 (en) | 2020-11-19 | 2024-09-12 | The Chinese University Of Hong Kong | Assessing risk for colorectal adenoma recurrence by noninvasive means |
| WO2023081167A2 (en) | 2021-11-02 | 2023-05-11 | The Regents Of The University Of California | P-selectin mutants and modulation of integrin-mediated signaling |
| US20250092106A1 (en) | 2022-01-25 | 2025-03-20 | The Regents Of The University Of California | Vegf mutants and modulation of integrin-mediated signaling |
| WO2024197185A1 (en) | 2023-03-21 | 2024-09-26 | The Broad Institute, Inc. | Methods and compositions for dissecting organelle physiology |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK55192D0 (da) | 1992-04-28 | 1992-04-28 | Lundbeck & Co As H | 1-piperazino-1,2-dihydroindenderivater |
| JP5043429B2 (ja) | 2003-08-18 | 2012-10-10 | ハー・ルンドベック・アクチエゼルスカベット | トランス−４−（（１ｒ，３ｓ）−６−クロロ−３−フェニルインダン−１−イル）−１，２，２−トリメチルピペラジンのコハク酸塩およびマロン酸塩、および薬剤としての使用方法 |
| RU2445095C2 (ru) | 2004-04-22 | 2012-03-20 | Бёрингер Ингельхайм Интернациональ Гмбх | Новые фармацевтические композиции для лечения сексуальных расстройств |
| CN103637977A (zh) | 2005-07-18 | 2014-03-19 | 宾夕法尼亚大学理事会 | 含药植入物及其使用方法 |
| NZ589571A (en) * | 2008-05-07 | 2012-07-27 | Lundbeck & Co As H | Method for treating cognitive deficits using trans-4-((1r,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine |
| AU2009298264A1 (en) * | 2008-10-03 | 2010-04-08 | H. Lundbeck A/S | Oral formulation |
| RU2012102247A (ru) * | 2009-06-24 | 2013-07-27 | Мсд Осс Б.В. | Инъекционные композиции, содержащие асенапин и способ лечения с их применением |
-
2012
- 2012-06-19 JO JOP/2012/0162A patent/JO3421B1/ar active
- 2012-06-19 TW TW101121870A patent/TWI552751B/zh not_active IP Right Cessation
- 2012-06-20 CA CA2838055A patent/CA2838055C/en not_active Expired - Fee Related
- 2012-06-20 RS RS20181311A patent/RS57944B1/sr unknown
- 2012-06-20 US US14/126,499 patent/US9610287B2/en active Active
- 2012-06-20 KR KR1020137033338A patent/KR101900989B1/ko not_active Expired - Fee Related
- 2012-06-20 LT LTEP12729555.8T patent/LT2720698T/lt unknown
- 2012-06-20 JP JP2014516318A patent/JP6140151B2/ja active Active
- 2012-06-20 ES ES12729555.8T patent/ES2694298T3/es active Active
- 2012-06-20 SI SI201231436T patent/SI2720698T1/sl unknown
- 2012-06-20 CN CN201280029452.1A patent/CN103608015A/zh active Pending
- 2012-06-20 SM SM20180567T patent/SMT201800567T1/it unknown
- 2012-06-20 MX MX2013014978A patent/MX349754B/es active IP Right Grant
- 2012-06-20 EP EP12729555.8A patent/EP2720698B1/en active Active
- 2012-06-20 AU AU2012274150A patent/AU2012274150B2/en not_active Ceased
- 2012-06-20 WO PCT/EP2012/061779 patent/WO2012175531A1/en not_active Ceased
- 2012-06-20 HR HRP20181684TT patent/HRP20181684T1/hr unknown
- 2012-06-20 BR BR112013032178A patent/BR112013032178A2/pt not_active Application Discontinuation
- 2012-06-20 PL PL12729555T patent/PL2720698T3/pl unknown
- 2012-06-20 DK DK12729555.8T patent/DK2720698T3/en active
- 2012-06-20 RU RU2014101482A patent/RU2613177C2/ru active
-
2013
- 2013-12-19 IL IL230060A patent/IL230060A/en active IP Right Grant
- 2013-12-19 ZA ZA2013/09617A patent/ZA201309617B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140033419A (ko) | 2014-03-18 |
| AU2012274150A1 (en) | 2014-01-09 |
| JP2014517050A (ja) | 2014-07-17 |
| HRP20181684T1 (hr) | 2018-12-14 |
| LT2720698T (lt) | 2018-11-12 |
| EP2720698B1 (en) | 2018-10-03 |
| RS57944B1 (sr) | 2019-01-31 |
| DK2720698T3 (en) | 2018-11-26 |
| TW201306840A (zh) | 2013-02-16 |
| RU2014101482A (ru) | 2015-07-27 |
| CN103608015A (zh) | 2014-02-26 |
| US9610287B2 (en) | 2017-04-04 |
| ES2694298T3 (es) | 2018-12-19 |
| ZA201309617B (en) | 2015-04-29 |
| MX349754B (es) | 2017-08-11 |
| RU2613177C2 (ru) | 2017-03-15 |
| KR101900989B1 (ko) | 2018-09-20 |
| PL2720698T3 (pl) | 2019-01-31 |
| MX2013014978A (es) | 2014-04-10 |
| JO3421B1 (ar) | 2019-10-20 |
| CA2838055A1 (en) | 2012-12-27 |
| TWI552751B (zh) | 2016-10-11 |
| BR112013032178A2 (pt) | 2016-12-20 |
| WO2012175531A1 (en) | 2012-12-27 |
| US20140194409A1 (en) | 2014-07-10 |
| CA2838055C (en) | 2021-01-26 |
| SI2720698T1 (sl) | 2018-12-31 |
| IL230060A (en) | 2017-10-31 |
| EP2720698A1 (en) | 2014-04-23 |
| SMT201800567T1 (it) | 2018-11-09 |
| AU2012274150B2 (en) | 2016-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6140151B2 (ja) | 統合失調症の処置において４−（（１ｒ，３ｓ）−６−クロロ−３−フェニル−インダン−１−イル）−１，２，２−トリメチル−ピペラジンおよびその塩を投与する方法 | |
| Miyamoto et al. | Antipsychotic drugs | |
| KR102133073B1 (ko) | 수면 장애 및 다른 장애를 치료하기 위한 방법 및 조성물 | |
| Davies et al. | Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology | |
| Richelson | Receptor pharmacology of neuroleptics: relation to clinical effects | |
| Baptista et al. | Pharmacological management of atypical antipsychotic-induced weight gain | |
| Abbas et al. | Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo | |
| JP2006515628A (ja) | ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用 | |
| Teegarden et al. | 5-HT2A inverse-agonists for the treatment of insomnia | |
| AU2018290889B2 (en) | NK-1 antagonist compositions and methods for use in treating depression | |
| CN107007603A (zh) | 使用环酰胺衍生物治疗σ受体介导的病症的方法 | |
| CN112955219A (zh) | 鲁潘立酮治疗阴性症状和病症、增加神经可塑性和促进神经保护的用途 | |
| TW201211021A (en) | Methods of use of cyclic amide derivatives to treat schizophrenia | |
| HK1196083B (en) | Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia | |
| HK1196083A (en) | Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia | |
| Singh et al. | An overview on asenapine maleate: PK-PD, preclinical and clinical update | |
| McCutcheon et al. | Drugs to treat schizophrenia and psychosis (dopamine antagonists and partial agonists other than clozapine) | |
| Cetin | Asenapine: A novel hope in the treatment of schizophrenia and manic and mixed episodes of bipolar I disorder | |
| Khazaal et al. | Topiramate for smoking cessation and the importance to distinguish withdrawal-motivated consumption and cue-triggered automatisms | |
| Grzelewska-Rzymowska et al. | Rupatadine: a novel second-generation antihistamine | |
| WO2020094592A1 (en) | Compounds for treating negative symptoms and cognitive impairments | |
| Weinberger et al. | Effects of topiramate on smoking in patients with schizoaffective disorder, bipolar type: response to Khazaal and Zullino | |
| Howes et al. | Sex hormone augmentation as an adjunctive treatment in schizophrenia | |
| TR201816155T4 (tr) | Şizofreni tedavisinde 4-((1r,3s)-6-kloro-3-fenil-indan-1-il)-1,2,2-trimetil-piperazin ve bunların tuzlarının uygulanmasına yönelik yöntem. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150603 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150603 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160405 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20160516 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160608 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20160927 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170317 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170425 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170428 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6140151 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |